• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition.数学建模研究 KRAS 突变体对通路抑制的特异性反应。
Methods Mol Biol. 2021;2262:311-321. doi: 10.1007/978-1-0716-1190-6_19.
2
A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.靶向治疗中 KRAS 突变等位基因特异性反应的系统机制。
Sci Signal. 2019 Sep 24;12(600):eaaw8288. doi: 10.1126/scisignal.aaw8288.
3
Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors.鉴别 KRAS G13D 结直肠癌对 EGFR 抑制剂敏感性的候选机制。
Cell Commun Signal. 2020 Nov 5;18(1):179. doi: 10.1186/s12964-020-00645-3.
4
Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach.使用系统生化方法鉴定 EGFR 抑制剂敏感性的 RAS 突变生物标志物。
Cell Rep. 2021 Dec 14;37(11):110096. doi: 10.1016/j.celrep.2021.110096.
5
KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer.KRAS G12C 抑制剂在转移性结直肠癌治疗中的应用。
Clin Colorectal Cancer. 2024 Sep;23(3):199-206. doi: 10.1016/j.clcc.2024.05.004. Epub 2024 May 13.
6
KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis.KRAS G13D 对神经纤维瘤介导的 GTP 水解的敏感性。
Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22122-22131. doi: 10.1073/pnas.1908353116. Epub 2019 Oct 14.
7
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.利用下一代测序技术对转移性结直肠癌患者进行超选择,以提高抗 EGFR 治疗的临床疗效。
Ann Oncol. 2019 Mar 1;30(3):439-446. doi: 10.1093/annonc/mdz005.
8
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.受体酪氨酸激酶依赖性 PI3K 激活是 KRAS 突变的人结直肠癌细胞系中 EGFR/RAS/MAPK 通路垂直抑制的逃逸机制。
J Exp Clin Cancer Res. 2019 Jan 28;38(1):41. doi: 10.1186/s13046-019-1035-0.
9
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.结直肠癌中针对 EGFR 阻断的获得性耐药的分子进化。
Nature. 2012 Jun 28;486(7404):537-40. doi: 10.1038/nature11219.
10
Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.比较KRAS G13D与其他KRAS突变转移性结直肠癌肿瘤中抗表皮生长因子受体(EGFR)单克隆抗体治疗疗效的荟萃分析。
Eur J Cancer. 2016 Mar;55:122-30. doi: 10.1016/j.ejca.2015.11.025. Epub 2016 Jan 23.

引用本文的文献

1
A guide to ERK dynamics, part 2: downstream decoding.ERK 动力学指南,第 2 部分:下游解码。
Biochem J. 2023 Dec 13;480(23):1909-1928. doi: 10.1042/BCJ20230277.
2
Computational Random Mutagenesis to Investigate RAS Mutant Signaling.通过计算随机诱变研究 RAS 突变体信号传导。
Methods Mol Biol. 2023;2634:329-335. doi: 10.1007/978-1-0716-3008-2_15.

本文引用的文献

1
A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.靶向治疗中 KRAS 突变等位基因特异性反应的系统机制。
Sci Signal. 2019 Sep 24;12(600):eaaw8288. doi: 10.1126/scisignal.aaw8288.
2
Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D.构象选择性地破坏活性位点揭示了 KRas G13D 内在激活的分子机制。
Cell Rep. 2019 Aug 6;28(6):1538-1550.e7. doi: 10.1016/j.celrep.2019.07.026.
3
Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.定量系统药理学分析 KRAS G12C 共价抑制剂。
CPT Pharmacometrics Syst Pharmacol. 2018 May;7(5):342-351. doi: 10.1002/psp4.12291. Epub 2018 Mar 25.
4
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study).西妥昔单抗对比伊立替康联合西妥昔单抗治疗化疗难治性KRAS密码子G13D转移性结直肠癌患者的随机II期研究(G13D研究)
Cancer Chemother Pharmacol. 2017 Jan;79(1):29-36. doi: 10.1007/s00280-016-3203-7. Epub 2016 Nov 22.
5
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.KRAS G13D 突变型难治性转移性结直肠癌患者使用西妥昔单抗联合或不联合伊立替康治疗的疗效:澳大利亚胃肠临床试验组 ICECREAM 研究。
J Clin Oncol. 2016 Jul 1;34(19):2258-64. doi: 10.1200/JCO.2015.65.6843. Epub 2016 Apr 25.
6
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.常见癌症相关 KRAS 突变的生化和结构分析。
Mol Cancer Res. 2015 Sep;13(9):1325-35. doi: 10.1158/1541-7786.MCR-15-0203. Epub 2015 Jun 2.
7
NMR-based functional profiling of RASopathies and oncogenic RAS mutations.基于 NMR 的 RAS 通路病和致癌性 RAS 突变的功能谱分析。
Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4574-9. doi: 10.1073/pnas.1218173110. Epub 2013 Mar 4.
8
Mathematical investigation of how oncogenic ras mutants promote ras signaling.致癌性Ras突变体如何促进Ras信号传导的数学研究。
Methods Mol Biol. 2012;880:69-85. doi: 10.1007/978-1-61779-833-7_5.
9
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.转移性结直肠癌患者中 KRAS 密码子 12 和 13 突变等位基因:作为 panitumumab 反应的预后和预测生物标志物的评估。
J Clin Oncol. 2013 Feb 20;31(6):759-65. doi: 10.1200/JCO.2012.45.1492. Epub 2012 Nov 26.
10
The response of cancers to BRAF inhibition underscores the importance of cancer systems biology.癌症对 BRAF 抑制的反应凸显了癌症系统生物学的重要性。
Sci Signal. 2012 Oct 16;5(246):pe46. doi: 10.1126/scisignal.2003354.

数学建模研究 KRAS 突变体对通路抑制的特异性反应。

Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition.

机构信息

Integrative Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA.

出版信息

Methods Mol Biol. 2021;2262:311-321. doi: 10.1007/978-1-0716-1190-6_19.

DOI:10.1007/978-1-0716-1190-6_19
PMID:33977486
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8639139/
Abstract

This chapter will describe how mathematical modeling allows the RAS pathway to be studied with computational experiments. The mathematical model utilized simulates the biochemical reactions that regulate RAS signaling. This type of model incorporates knowledge of reaction mechanisms, including measured quantitative parameters that characterize these reactions for both wild-type and mutant RAS proteins. For an illustrative example, this chapter focuses on how modeling provided new insights that helped solve a problem that challenged the RAS community for nearly a decade: why do colorectal cancers with the KRAS G13D mutation, but not the other common KRAS mutations, benefit from EGFR inhibition? The methods described include computational dose-response experiments and the use of "computational chimeric" RAS mutants.

摘要

本章将介绍如何通过计算实验来研究 RAS 通路,使用的数学模型模拟了调节 RAS 信号的生化反应。该模型结合了反应机制的知识,包括用于野生型和突变型 RAS 蛋白的这些反应的测量定量参数。作为一个说明性示例,本章重点介绍了建模如何提供新的见解,帮助解决了 RAS 领域近十年来一直面临的挑战:为什么具有 KRAS G13D 突变的结直肠癌受益于 EGFR 抑制,而不是其他常见的 KRAS 突变?所描述的方法包括计算剂量反应实验和使用“计算嵌合”RAS 突变体。